Login / Register for free to get access to My MedWorm
MedWorm: Current Discussions on Medical News and Literature RSS FeedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. subscribe with Google ReaderSubscribe to this data using GoogleReader. subscribe with BloglinesSubscribe to this data using Bloglines. subscribe to this feed to follow all MedWorm discussions

Subject: Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Subject:

Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)email this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI).
Source: Dermatology News From Medical News Today - November 7, 2009 Category: Dermatology Tags: Dermatology Source Type: news

Discussion:

MedWorm Notice: Any discussion posted on this page does not represent MedWorm's opinion. MedWorm does not publish its own articles but provides a means of distribution for publishers and it does not express any opinion or give advice, but provides a forum for free discussion for its website visitors. Please always consult your own doctor before following any course of medical treatment.

You can start a discussion on this item by clicking on the Add Comment button.